The Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG)

Vaccine

Volumn 33, Issue 1, 2015, Pages 73-75

  Chen, Robert T ^a   Carbery, Baevin ^a,b   Mac, Lisa ^a   Berns, Kenneth I ^c   Chapman, Louisa ^a   Condit, Richard C ^c   Excler, Jean Louis ^d,e   Gurwith, Marc ^f   Hendry, Michael ^a   Khan, Arifa S ^g   Khuri Bulos, Najwa ^h   Klug, Bettina ⁱ   Robertson, James S ^j   Seligman, Stephen J ^k   Sheets, Rebecca ^l   Williamson, Anna Lise ^m  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^c UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^d INTERNATIONAL AIDS VACCINE INITIATIVE   (United States)

^e US Military HIV Research Program (MHRP)   (United States)

^f PaxVax ^*  (United States)

^g CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

^h JORDAN UNIVERSITY HOSPITAL   (Jordan)

ⁱ PAUL EHRLICH INSTITUT   (Germany)

^j NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

^k NEW YORK MEDICAL COLLEGE   (United States)

^l NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^m NATIONAL HEALTH LABORATORY SERVICE   (South Africa)

more..

Author keywords

Immunization; Safety; Vaccines; Viral Vector

Indexed keywords

EBOLA VACCINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; VACCINE; VIRUS VECTOR; YELLOW FEVER VACCINE; DRUG CARRIER; RECOMBINANT VACCINE; VIRUS VACCINE;

DATA ANALYSIS; DRUG RESEARCH; DRUG SAFETY; HEALTH CARE ORGANIZATION; HUMAN; IMMUNIZATION; LICENSING; MEDICAL LITERATURE; NONHUMAN; NOTE; RISK BENEFIT ANALYSIS; WORLD HEALTH ORGANIZATION; CLINICAL TRIAL (TOPIC); DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; GENE VECTOR; GENETICS; IMMUNOLOGY; INTERNATIONAL COOPERATION;

CLINICAL TRIALS AS TOPIC; DRUG CARRIERS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; GENETIC VECTORS; HUMANS; INTERNATIONAL COOPERATION; VACCINES, SYNTHETIC; VIRAL VACCINES;

EID: 84919417723     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.09.035     Document Type: Note

References (36)

1. Bonhoeffer J., Kohl K., Chen R., Duclos P., Heijbel H., Heininger U., et al. The Brighton Collaboration: addressing the need for standardized case definitions of adverse events following immunization (AEFI). Vaccine 2002, 21(3-4):298-302.
2. MacDonald N.E., Smith J., Appleton M. Risk perception, risk management and safety assessment: what can governments do to increase public confidence in their vaccine system?. Biologicals 2012, 40(5):384-388.
3. Amarasinghe A., Black S., Bonhoeffer J., Carvalho S.M., Dodoo A., Eskola J., et al. Effective vaccine safety systems in all countries: a challenge for more equitable access to immunization. Vaccine 2013, 31(Suppl. 2):B108-B114.
4. Chen R.T., Hibbs B. Vaccine safety: current and future challenges. Pediatr Ann 1998, 27(7):445-455.
5. Kohl K.S., Bonhoeffer J., Chen R., Duclos P., Heijbel H., Heininger U., et al. The Brighton Collaboration: enhancing comparability of vaccine safety data. Pharmacoepidemiol Drug Saf 2003, 12(4):335-340.
6. Pharmacovigilance C.W.W.G.o.V. Vaccine Pharmacovigilance 2013, Available from: http://www.cioms.ch/index.php/vaccine-pharmacovigilance [accessed 20.11.13].
7. CDER C.f.D.E.a.R., Guidance for Industry and FDA Staff: Best Practices for Conducting and Reporting Pharmacoepidemiologic Safety Studies Using Electronic Healthcare Data May 2013.
8. C.f.M.P.f.H. Guideline on the conduct of pharmacovigilance for vaccine for pre- and post-exposure prophylaxis against infectious diseases. EMEA/CHMP/PhVWP/503449/2007 2009, E.M. Agency, London.
9. Velazquez F.R., Colindres R.E., Grajales C., Hernandez M.T., Mercadillo M.G., Torres F.J., et al. Postmarketing surveillance of intussusception following mass introduction of the attenuated human rotavirus vaccine in Mexico. Pediatr Infect Dis J 2012, 31(7):736-744.
10. Greene S.K., Rett M., Weintraub E.S., Li L., Yin R., Amato A.A., et al. Risk of confirmed Guillain-Barre syndrome following receipt of monovalent inactivated influenza A (H1N1) and seasonal influenza vaccines in the Vaccine Safety Datalink Project, 2009-2010. Am J Epidemiol 2012, 175(11):1100-1109.
11. Dauvilliers Y., Arnulf I., Lecendreux M., Monaca Charley C., Franco P., Drouot X., et al. Increased risk of narcolepsy in children and adults after pandemic H1N1 vaccination in France. Brain 2013, 136(Pt 8):2486-2496.
12. Salmon D.A., Pavia A., Gellin B. Editors' introduction: vaccine safety throughout the product life cycle. Pediatrics 2011, 127(Suppl. 1):S1-S4.
13. Rennels M.B. The rotavirus vaccine story: a clinical investigator's view. Pediatrics 2000, 106(1 Pt 1):123-125.
14. Curlin G., Landry S., Bernstein J., Gorman R.L., Mulach B., Hackett C.J., et al. Integrating safety and efficacy evaluation throughout vaccine research and development. Pediatrics 2011, 127(Suppl. 1):S9-S15.
15. Bonhoeffer J., Bentsi-Enchill A., Chen R.T., Fisher M.C., Gold M.S., Hartman K., et al. Guidelines for collection, analysis and presentation of vaccine safety data in pre- and post-licensure clinical studies. Vaccine 2009, 27(16):2282-2288.
16. Bonhoeffer J., Imoukhuede E.B., Aldrovandi G., Bachtiar N.S., Chan E.S., Chang S., et al. Template protocol for clinical trials investigating vaccines - focus on safety elements. Vaccine 2013, 31(47):5602-5620.
17. Plotkin S.A. Vaccines: the fourth century. Clin Vaccine Immunol 2009, 16(12):1709-1719.
18. Liniger M., Zuniga A., Naim H.Y. Use of viral vectors for the development of vaccines. Expert Rev Vaccines 2007, 6(2):255-266.
19. Excler J.L., Parks C.L., Ackland J., Rees H., Gust I.D., Koff W.C. Replicating viral vectors as HIV vaccines: summary report from the IAVI-sponsored satellite symposium at the AIDS vaccine 2009 conference. Biologicals 2010, 38(4):511-521.
20. Naim H.Y. Applications and challenges of multivalent recombinant vaccines. Hum Vaccine Immunother 2012, 9.(3).
21. Xing Z., Lichty B.D. Use of recombinant virus-vectored tuberculosis vaccines for respiratory mucosal immunization. Tuberculosis (Edinb) 2006, 86(3-4):211-217.
22. Limbach K.J., Richie T.L. Viral vectors in malaria vaccine development. Parasite Immunol 2009, 31(9):501-519.
23. Small J.C., Ertl H.C. Viruses - from pathogens to vaccine carriers. Curr Opin Virol 2011, 1(4):241-245.
24. Draper S.J., Heeney J.L. Viruses as vaccine vectors for infectious diseases and cancer. Nat Rev Microbiol 2010, 8(1):62-73.
25. Parks C.L., Picker L.J., King C.R. Development of replication-competent viral vectors for HIV vaccine delivery. Curr Opin HIV AIDS 2013, 8(5):402-411.
26. Johnson J.A., Barouch D.H., Baden L.R. Nonreplicating vectors in HIV vaccines. Curr Opin HIV AIDS 2013, 8(5):412-420.
27. WHO Initiative for Vaccine Research. WHO informal consultation on characterization and quality aspect of vaccines based on live viral vectors December 2003, Available from: http://www.who.int/vaccine_research/documents/vvreport/en/index1.html.
28. (CHMP), C.f.M.P.f.H.U. Guideline on quality, non-clinical and clinical aspects of live recombinant viral vectored vaccines. EMA/CHMP/VWP/141697/2009 2010, E.M. Agency, London, UK.
29. Butler D. Blood transfusion called priority Ebola therapy. Nature news 2014, Nature Publishing.
30. Buchbinder S.P., Mehrotra D.V., Duerr A., Fitzgerald D.W., Mogg R., Li D., et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 2008, 372(9653):1881-1893.
31. Duerr A., Huang Y., Buchbinder S., Coombs R.W., Sanchez J., del Rio C., et al. Extended follow-up confirms early vaccine-enhanced risk of HIV acquisition and demonstrates waning effect over time among participants in a randomized trial of recombinant adenovirus HIV vaccine (Step Study). J Infect Dis 2012, 206(2):258-266.
32. Gray G.E., Allen M., Moodie Z., Churchyard G., Bekker L.G., Nchabeleng M., et al. Safety and efficacy of the HVTN 503/Phambili study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b study. Lancet Infect Dis 2011, 11(7):507-515.
33. Rerks-Ngarm S., Pitisuttithum P., Nitayaphan S., Kaewkungwal J., Chiu J., Paris R., et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009, 361(23):2209-2220.
34. Hansen S.G., Piatak M., Ventura A.B., Hughes C.M., Gilbride R.M., Ford J.C., et al. Immune clearance of highly pathogenic SIV infection. Nature 2013, 502(7469):100-104.
35. Monath T.P., Sea S. V3SWG template on risk/benefit assessment for live virus vaccines based on a yellow fever vaccine backbone vaccine 2014.
36. Alonso P.L., de Quadros C.A., Robert M., Lal A.A. Decade of vaccines, Editorial. Vaccine 2013, 31(Suppl. 2):B3-B4.